Leela Barham digs into what’s publicly available on the success of NICE Advice just as the institute launched a refreshed offer to life sciences companies.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh